Pfizer (NYSE:PFE) Trading Up 0.5%

Shares of Pfizer Inc. (NYSE:PFE - Get Free Report) rose 0.5% on Tuesday . The stock traded as high as $26.47 and last traded at $26.38. Approximately 5,125,726 shares were traded during trading, a decline of 88% from the average daily volume of 41,850,047 shares. The stock had previously closed at $26.26.

Analysts Set New Price Targets

PFE has been the subject of several research analyst reports. Argus lowered shares of Pfizer from a "buy" rating to a "hold" rating in a research note on Friday, March 22nd. TD Cowen lowered shares of Pfizer from an "outperform" rating to a "market perform" rating and set a $32.00 target price for the company. in a research note on Thursday, January 4th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $45.00 target price on shares of Pfizer in a research note on Monday, April 15th. Finally, Guggenheim assumed coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a "buy" rating and a $36.00 price target on the stock. Eleven research analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat.com, Pfizer currently has an average rating of "Hold" and a consensus price target of $36.33.

Pfizer Trading Up 0.2 %

The company's fifty day moving average is $27.07 and its two-hundred day moving average is $28.52. The stock has a market cap of $149.04 billion, a price-to-earnings ratio of 73.11, a PEG ratio of 1.17 and a beta of 0.61. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm had revenue of $14.25 billion for the quarter, compared to analysts' expectations of $14.37 billion. During the same quarter last year, the company earned $1.14 earnings per share. The firm's revenue was down 41.3% compared to the same quarter last year. On average, research analysts predict that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Institutional Trading of Pfizer

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Briaud Financial Planning Inc purchased a new position in shares of Pfizer during the third quarter worth approximately $30,000. GoalVest Advisory LLC grew its position in Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company's stock valued at $31,000 after buying an additional 811 shares during the last quarter. Creekmur Asset Management LLC purchased a new position in Pfizer in the 4th quarter valued at $32,000. Trivant Custom Portfolio Group LLC lifted its holdings in Pfizer by 100.0% in the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company's stock valued at $33,000 after acquiring an additional 600 shares during the period. Finally, Mizuho Securities Co. Ltd. acquired a new stake in Pfizer in the third quarter valued at $34,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.